Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.70 |
| ▸ | MME | P08473 | 1/20 | 0.64 |
| ▸ | ECE1 | P42892 | 1/20 | 0.64 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.61 |
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28226069 | 1.00 | FOLH1 (0.70) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL910232 | 1.00 | FOLH1 (0.70) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL910423 | 1.00 | FOLH1 (0.70) | FOLH1MMEECE1NAALAD2PPARA | |
| Cyclopropane SCHEMBL5691187 | 0.96 | FOLH1 (0.65) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL24238520 | 0.95 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL9697060 | 0.95 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL19925534 | 0.95 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL9698236 | 0.95 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL9697579 | 0.95 | MME (0.65) | FOLH1MMEECE1NAALAD2CASP1 | |
| SCHEMBL19307785 | 0.95 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031663-A | Erythrocyte-like artificial oxygen carrier therapeutic agent and preparation method and application thereof | 南京鼓楼医院 | 2026-05-15 | — | — | CN | claimed |
| CN-119930561-A | Raltitrexed initial raw material reference substance impurity as well as preparation method and application thereof | 江苏天士力帝益药业有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-112557572-B | Method for detecting isomer content in Cbz-Glu | 成都普康生物科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115160430-B | Synthesis method of main chain segment of cable Ma Lutai | 成都普康唯新生物科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-110317258-B | New polypeptide fragment of somaglutide and preparation method thereof | 齐鲁制药有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-115594736-A | Bionic nano-medicament for improving curative effect of radiotherapy and chemotherapy, preparation method and application thereof | 南京脑科医院（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-114133398-B | Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof | 中南民族大学 | 2022-11-22 | — | — | CN | claimed |
| CN-115160430-A | Synthesis method of somaglutide backbone fragment | 成都普康唯新生物科技有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-114133398-A | Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof | 中南民族大学 | 2022-03-04 | — | — | CN | claimed |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | claimed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | claimed |
| US-6398857-B1 | ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS | XEROX CORPORATION | 2002-06-04 | — | — | US | claimed |
| US-6395077-B1 | INKS WITH BENZOYLBENZOIC ACID AND COLORS | XEROX CORPORATION | 2002-05-28 | — | — | US | claimed |
| US-5990266-A | Degradable polyesters, a mixed culture of microorganisms for degrading these polyesters, and methods for making these substances | UNIVERSITY OF NEBRASKA (US) | 1999-11-23 | — | — | US | claimed |
| WO-1999028366-A1 | DEGRADABLE POLYESTERS | BOARD OF REGENTS OF UNIVERSITY OF NEBRASKA (US) | 1999-06-10 | — | — | WO | claimed |
| EP-0624599-B1 | Derivatives of mono (6-amino-desoxy)cyclodextrin substituted in position 6 with an alpha aminoacid group, process of their preparation and applications | OREAL (FR) | 1997-07-30 | — | — | EP | claimed |
| EP-0624599-A2 | Derivatives of mono (6-amino-desoxy)cyclodextrin substituted in position 6 with an alpha aminoacid group, process of their preparation and applications | L'OREAL (FR) | 1994-11-17 | — | — | EP | claimed |
| WO-1993005046-A1 | AMINODIESTERS OF RAPAMYCIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-03-18 | — | — | WO | claimed |
| US-5162333-A | Treating transplantation rejection, autoimmune diseases, antiinflammatory | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-11-10 | — | — | US | claimed |
| EP-0292228-A2 | Protecting groups for asparagine and glutamine in peptide synthesis | MILLIPORE CORPORATION (US) | 1988-11-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | GOT1, ACAT1, GOT2 | FOLH1 281/4885MME 613/4885ECE1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.